The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | N | Nervous system | |
2 | N07 | Other nervous system drugs | |
3 | N07X | Other nervous system drugs |
Code | Title | |
---|---|---|
N07XA | Gangliosides and ganglioside derivatives | |
N07XX | Other nervous system drugs |
Active Ingredient | Description | |
---|---|---|
Amifampridine |
Amifampridine blocks voltage-dependent potassium channels, thereby prolonging pre-synaptic cell membrane depolarisation. Prolonging the action potential enhances the transport of calcium into the nerve ending. The resulting increase in intra-cellular calcium concentrations facilitates exocytosis of acetylcholine-containing vesicles, which in turn enhances neuromuscular transmission. |
|
Edaravone |
Edaravone is a member of the substituted 2-pyrazolin-5-one class. It is used for the treatment of amyotrophic lateral sclerosis (ALS). The mechanism by which edaravone exerts its therapeutic effect in patients with ALS is unknown. |
|
Eplontersen |
Eplontersen is an antisense oligonucleotide-GalNAc conjugate that causes degradation of mutant and wild-type TTR mRNA through binding to the TTR mRNA, which results in a reduction of serum TTR protein and TTR protein deposits in tissues. |
|
Fampridine |
Fampridine is a potassium channel blocker. By blocking potassium channels, fampridine reduces the leakage of ionic current through these channels, thereby prolonging repolarization and thus enhancing action potential formation in demyelinated axons and neurological function. |
|
Inotersen |
Inotersen is an antisense oligonucleotide that causes degradation of mutant and wild-type TTR mRNA through binding to the TTR mRNA, which results in a reduction of serum TTR protein and TTR protein deposits in tissues. It is used for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults. |
|
Patisiran |
Patisiran is a double-stranded small interfering ribonucleic acid (siRNA) that specifically targets a genetically conserved sequence in the 3’ untranslated region of all mutant and wild-type TTR mRNA. Through a natural process called RNA interference (RNAi), patisiran causes the catalytic degradation of TTR mRNA in the liver, resulting in a reduction of serum TTR protein, a carrier of retinol binding protein which facilitates transport of vitamin A in the blood. |
|
Pitolisant |
Pitolisant is a potent, orally active histamine H3-receptor antagonist/inverse agonist which, via its blockade of histamine auto-receptors enhances the activity of brain histaminergic neurons, a major arousal system with widespread projections to the whole brain. Pitolisant also modulates various neurotransmitter systems, increasing acetylcholine, noradrenaline and dopamine release in the brain. |
|
Riluzole |
Riluzole is proposed to act by inhibiting glutamate processes. The mode of action is unclear. It is suggested that glutamate (the primary excitatory neurotransmitter in the central nervous system) plays a role for cell death in the ALS disease. |
|
Sodium oxybate |
|
|
Tafamidis |
Tafamidis is a selective stabiliser of transthyretin (TTR). Tafamidis binds to TTR at the thyroxine binding sites, stabilising the tetramer and slowing dissociation into monomers, the rate-limiting step in the pathogenesis of transthyretin amyloidosis. |
|
Tetrabenazine |
Tetrabenazine is a synthetic derivative of benzylquinolizine that causes depletion of dopamine and other monoamines in the central nervous system. The precise mechanism by which tetrabenazine exerts its effects is unknown, but is believed to be related to its effect as a reversible depletor of monoamines (such as dopamine, serotonin, norepinephrine, and histamine) from nerve terminals. Neurotransmitter depletion by a single dose of tetrabenazine is reversible and lasts only a few hours. |
|
Tirilazad |
|
|
Tofersen |
Tofersen is an antisense oligonucleotide that causes degradation of SOD1 mRNA through binding to SOD1 mRNA, which results in a reduction of SOD1 protein synthesis. Tofersen is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. |
|
Valbenazine |
Valbenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor. The mechanism of action of valbenazine in the treatment of tardive dyskinesia is unknown, but is thought to be mediated through the reversible inhibition of VMAT2, a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release. |
|
Vutrisiran |
Vutrisiran is covalently linked to a ligand containing three N-acetylgalactosamine (GalNAc) residues to enable delivery of the siRNA to hepatocytes. Through a natural process called RNA interference (RNAi), vutrisiran causes the catalytic degradation of TTR mRNA in the liver, resulting in the reduction of variant and wild-type serum TTR protein levels. |
Title | Information Source | Document Type | |
---|---|---|---|
AMVUTTRA Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
FAMPYRA Prolonged-release tablets | European Medicines Agency (EU) | MPI, EU: SmPC | |
FIRDAPSE Tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
FIRDAPSE Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
NITOMAN Tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
ONPATTRO Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
OZAWADE Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
QALSODY Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
RADICAVA Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
RILUTEK Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
RUZURGI Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
TEGSEDI Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
VYNDAMAX Capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
VYNDAQEL 20 mg Soft capsule | European Medicines Agency (EU) | MPI, EU: SmPC | |
WAINUA Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
WAKIX Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
XENAZINE Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
XYREM Solution | FDA, National Drug Code (US) | MPI, US: SPL/PLR |